陆金健

男， 澳门大学， 教授/研究员/教授级高工或同等级别

学习/工作经历

工作经历
教授、助理院长，2024年8月至今
澳门大学中华医药研究院、中药质量研究国家重点实验室

学习经历
药理学 博士，2009年7月，中国科学院上海药物研究所
生物科学 学士，2004年7月，浙江师范大学

研究领域和兴趣

抗肿瘤药物研发

主要业绩

从事抗肿瘤化合物发现及机制研究，抗肿瘤新靶点及新策略研究等。获国家自然科学基金、澳门科学技术发展基金等10余项资助，在SCI期刊上发表论文200余篇，总被引10000余次，H影响因子56，入选年度全球前2%顶尖科学家榜单及全球学者学术影响力排行榜。申请专利10余项。获澳门科学技术奖自然科学奖二等奖（两次）等。为10余本期刊副主编、编委或青年编委，Chinese Medicine编辑部副主任，担任国家自然科学基金、香港健康与医学研究基金、法国国家研究所等项目同行评审，受邀在海内外学术大会及高校报告70余次。现任澳门精准医学学会副理事长、中国药理学会中药与天然药物药理专委会青委会副主任委员、中国药理学会抗炎免疫药理专委会委员、中国中西医结合学会中药专委会常务委员、世中联李时珍医药研究与应用专委会常务理事、中国康复医学会药学与康复专委会常务委员、中华中医药学会中药实验药理分会委员等。

代表成果

*Corresponding or co-corresponding author
Huang MY, Chen YC, Lyu WY, He XY, Ye ZH, Huang CY, He XL, Chen X, Chen X, Zhang B, Kai G, Zhang X, Li T*, Huang M*, Lu JJ*. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10. Pharmacological Research. 2023, 106988.
Ye ZH, Yu WB, Huang MY, Chen J, Lu JJ*. Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives. Acta Pharmaceutica Sinica B. 2023, 13(4): 1467-87.
Yu WB, Chen YC, Huang CY, Ye ZH, Shi W, Zhu H, Shi JJ, Chen J, Lu JJ*. CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer. Frontiers of Medicine. 2023, 17(1): 105-118.
Xu YL, Yuan LW, Jiang XM, Su MX, Huang MY, Chen YC, Zhang LL, Chen X, Zhu H, Lu JJ*. Glutathione peroxidase 8 expression on cancer cells and cancer-associated fibroblasts facilitates lung cancer metastasis. MedComm. 2022, 3(3): e152.
Chen YC, HE XL, Qi L, Shi W, Yuan LW, Huang MY, Xu YL, Chen X, Gu L, Zhang LL, Lu JJ*. Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells. Biochemical Pharmacology. 2022, 197: 114940.
Su MX, Xu YL, Jiang XM, Huang MY, Zhang LL, Yuan LW, Xu XH, Zhu Q, Gao JL, Lu JH, Chen X, Huang MQ, Wang Y, Lu JJ*. c-MYC-mediated TRIB3/P62+ aggresomes accumulation triggers paraptosis upon the combination of everolimus and ginsenoside Rh2. Acta Pharmaceutica Sinica B. 2022, 12(3): 1240-53.
Huang MY, Jiang XM, Wang BL, Sun Y, Lu JJ*. Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. Pharmacology & Therapeutics. 2021, 219: 107694.
Yuan LW, Jiang XM, Xu YL, Huang MY, Chen YC, Yu WB, Su MX, Ye ZH, Chen X, Wang Y, Lu JJ*. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells. Phytomedicine. 2021, 80: 153394.
Yu WB, Ye ZH, Chen X, Shi JJ*, Lu JJ*. The development of small-molecule inhibitors targeting CD47. Drug Discovery Today, 2021, 26(2): 561-68.
Jiang XM, Xu YL, Yuan LW, Zhang LL, Huang MY, Ye ZH, Su MX, Chen X, Zhu H, Ye R, Lu JJ*. TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance. Acta Pharmacologica Sinica. 2021, 42: 451-9.
Li T, Xu XH, Guo X, Yuan T, Tang ZH, Jiang XM, Xu YL, Zhang LL, Chen X, Zhu H, Shi JJ, Lu JJ*. Activation of Notch 3/c-MYC/CHOP axis regulates apoptosis and promotes sensitivity of lung cancer cells to mTOR inhibitor everolimus. Biochemical Pharmacology. 2020, 175: 113921.
Zhang LL, Guo J, Jiang XM, Chen X, Wang Y, Li A, Lin LG*, Li H*, Lu JJ*. Identification of nagilactone E as a protein synthesis inhibitor with anticancer activity. Acta Pharmacologica Sinica. 2020, 41: 698-705.
Huang MY, Jiang XM*, Xu YL, Yuan LW, Chen YC, Cui G, Huang RY, Liu B, Wang Y, Chen X, Lu JJ*. Platycodin D triggers the extracellular release of programed death Ligand-1 in lung cancer cells. Food and Chemical Toxicology. 2019, 131: 110537.
Zhang LL, Jiang XM, Huang MY, Feng ZL, Chen X, Wang Y, Li H, Li A, Lin LG*, Lu JJ*. Nagilactone E suppresses TGF-β1-induced epithelial–mesenchymal transition, migration and invasion in non-small cell lung cancer cells. Phytomedicine. 2019, 52: 32-9.
Cao WX, Li T, Tang ZH, Zhang LL, Wang ZY, Guo X, Su MX, Chen X, Lu JJ*. MLKL mediates apoptosis via a mutual regulation with PERK/eIF2α pathway in response to reactive oxygen species generation. Apoptosis. 2018, 23(9-10): 521-31.
Li T, Jiang HL, Tong YG, Lu JJ*. Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery. Journal of Hematology & Oncology. 2018, 11: 59.
Tang ZH, Cao WX, Guo X, Dai XY, Lu JH, Chen X, Zhu H, Lu JJ*. Identification of a novel autophagic inhibitor cepharanthine to enhance the anti-cancer property of dacomitinib in non-small cell lung cancer. Cancer Letters. 2018, 412: 1-9.
Tang ZH, Lu JJ*. Osimertinib resistance in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Letters. 2018, 420: 242-6.

*以上信息由高级会员个人更新和维护。